AK106-001616

AK106-001616 is a novel, potent, and selective small molecule inhibitor of cytosolic phospholipase A2 (cPLA2). It reduces the production of pro-inflammatory mediators such as prostaglandin E2 (PGE2) and leukotriene B4 (LTB4), distinguishing it from traditional nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors. Preclinical studies have shown that AK106-001616 alleviates inflammation in animal models of arthritis, neuropathic pain, and pulmonary fibrosis without increasing gastrointestinal or cardiovascular risks. The drug has demonstrated efficacy comparable to or greater than naproxen in certain arthritis models and has shown neuroprotective effects in cell-based assays. AK106-001616 was developed primarily for the treatment of rheumatoid arthritis and has completed multiple phase 2 clinical trials for this indication[1][2][3][4][5][6].

Other names

3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1h-indazol-5-yl)-phenyl]-propionic acid